TORONTO and CHICAGO and WEDEL, Germany, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) and medac GmbH (“medac”) announced...
TORONTO and CHICAGO, July 19, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce the appointment of Marcel Konrad...
TORONTO and CHICAGO and WEDEL, Germany, July 12, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that it has entered...
TORONTO and CHICAGO, June 28, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that it has received a Notice of...
Transformative licensing agreement for treosulfan in the U.S. completed February 2, 2021 Cash and cash equivalents of $18.7 million and available liquidity of $24.8 million at March 31, 2021...
TORONTO and CHICAGO and MONTREAL, June 15, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSXV:MDP) (OTCQX: MEDXF) announced today that it has received final...
TORONTO, CHICAGO and MONTREAL, June 14, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it...
TORONTO and CHICAGO and MONTREAL, June 11, 2021 (GLOBE NEWSWIRE) -- , June 11, 2021 - Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) today...
TORONTO, CHICAGO and MONTREAL, June 10, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) today announced that it...
TORONTO and CHICAGO and MONTREAL, June 09, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 7.75 | 7.75 | 7.75 | 0 | 0 | CS |
4 | 0 | 0 | 7.75 | 7.75 | 7.75 | 0 | 0 | CS |
12 | 0 | 0 | 7.75 | 7.75 | 7.75 | 0 | 0 | CS |
26 | 0 | 0 | 7.75 | 7.75 | 7.75 | 0 | 0 | CS |
52 | 0 | 0 | 7.75 | 7.75 | 7.75 | 0 | 0 | CS |
156 | 0 | 0 | 7.75 | 7.75 | 7.75 | 0 | 0 | CS |
260 | 3.51 | 82.7830188679 | 4.24 | 9.75 | 1.42 | 8437 | 6.77809156 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales